Zafgen Refocuses Resources on Development of Differentiated Second-Generation MetAP2 Inhibitor ZGN-1061
-ZGN-1061 in Phase I Development for Severe and Complicated Obesity Indications- - Suspending Development of Beloranib; Implementing Strategic Restructuring to Align Operations with Clinical Development Priorities- -Strong Cash Position Sufficient to Fund …